Table 5

TRA-PCI Cohort Results at 60 Days of an Oral Selective TRA

Placebo (n = 151)SCH 530348
All (n = 422)10 mg (n = 129)20 mg (n = 120)40 mg (n = 173)
TIMI major/minor5 (3.3%)12 (2.8%)2 (1.6%)3 (2.5%)7 (4.0%)
Non–TIMI bleeding48 (32%)173 (41%)47 (36%)52 (43%)74 (43%)
Death/MACE13 (8.6%)25 (5.9%)11 (8.5%)6 (5.0%)8 (4.6%)
MI11 (7.3%)11 (7.3%)7 (5.4%)5 (4.2%)6 (3.5%)

MACE = major adverse cardiac event; MI = myocardial infarction; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction; TRA = thrombin receptor antagonist.

  • Primary end point (safety); secondary end point (efficacy).